Short answer
GERON CORP (GERN) filed its fiscal 2025 10-K annual report with the SEC on Mar 2, 2026.
- Top risk flagged: Regulatory risk: Uncertainty in RYTELO approval beyond U.S. FDA and EU marketing authorization, affecting future launch timing and revenue generation
FY2025 key financial metrics · XBRL
- Net income
- −$84M
- +52.2% YoY
- EPS (diluted)
- −$0.13
- +51.9% YoY
- ROE
- -37.0%
- +25.3 pp YoY
- Operating cash flow
- −$111M
- +49.2% YoY
Source: XBRL data from the GERON CORP (GERN) FY2025 10-K on SEC EDGAR. USD.
GERON CORP FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business model: Biopharmaceutical company focused on cancer therapeutics development
- No new products, services, or segments introduced or emphasized in this filing year
- Continued emphasis on corporate governance with established Code of Conduct and Insider Trading Policy
- No quantitative metrics disclosed in Business section; governance details referenced extensively to Proxy Statement
- Unusual fact: Entire Business section replaced by governance, ethics, and reference to Proxy Statement, lacking typical operational details
Management Discussion & Analysis
- Risks focus on commercialization, regulatory approvals, clinical trial outcomes, manufacturing, and market acceptance of RYTELO (imetelstat)
- Forward-looking risks include FDA/EC approval timelines, clinical trial delays, competitive pressures, and macroeconomic impacts on operations
Risk Factors
- Regulatory risk: Uncertainty in RYTELO approval beyond U.S. FDA and EU marketing authorization, affecting future launch timing and revenue generation
- Macroeconomic risk: Exposure to inflation, trade tensions, interest rate fluctuations, and global crises impacting financing and operations
- Supply chain risk: $60 million in manufacturing commitments for RYTELO requiring long lead-times and incurring cancellation penalties
- Competitive risk: Potential market disruption if RYTELO commercialization fails or competitors advance alternative myelodysplastic syndrome treatments
- Financial risk: $119.5 million long-term debt principal with covenants and maturity in 2029, plus $141 million net proceeds dilution risk from equity offerings
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.